Study on Preventing Chronic Pain After Hernia and Knee Surgery Using Tapentadol for Patients Undergoing These Surgeries

3 1 1 1

What is this study about?

This clinical trial is focused on studying the prevention of chronic postoperative pain, which is pain that persists after surgery, specifically following inguinal hernia surgery and knee replacement surgery. The treatment being tested in this study is a medication called Tapentadol, which is provided in the form of a prolonged-release tablet known as PALEXIA Retard 50 mg. This medication is taken orally, meaning it is swallowed. The study also involves a comparison with a placebo to evaluate the effectiveness of Tapentadol in preventing chronic pain after surgery.

The purpose of the study is to explore whether using Tapentadol after surgery can help prevent the development of chronic pain in patients who have undergone inguinal hernia or knee replacement surgeries. Participants in the study will receive either Tapentadol or a placebo after their surgery. The study will monitor the development of chronic pain over the course of the first year following the surgery to determine the effectiveness of the treatment.

By participating in this study, researchers aim to gain a better understanding of how chronic postoperative pain develops and whether Tapentadol can be an effective treatment to prevent it. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. The trial is expected to continue until early 2026.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria such as age between 18-80 years and an American Society of Anesthesiologists score of 1, 2, or 3.

2 surgery preparation

Preparation for either inguinal hernia surgery or knee replacement surgery is undertaken. This involves standard pre-surgical procedures.

3 surgery

The patient undergoes the planned surgical procedure, which is either inguinal hernia surgery or knee replacement surgery.

4 postoperative treatment

Following surgery, the patient receives postoperative treatment with tapentadol hydrochloride or a placebo. The medication is administered orally in the form of a prolonged-release tablet known as PALEXIA Retard 50 mg.

The dosage and frequency of administration are determined by the study protocol and are designed to prevent the development of chronic postoperative pain.

5 monitoring and follow-up

The patient’s response to the treatment is monitored over the course of one year. This includes regular assessments to evaluate the effect of tapentadol compared to the placebo on the development of chronic pain.

The study aims to understand the mechanism behind the development of chronic postoperative pain.

6 completion of study

The study is estimated to conclude by January 1, 2026. At this point, the final assessments are conducted to gather data on the primary endpoint, which is the effect of the treatment on chronic pain development.

Who Can Join the Study?

Must have an American Society of Anesthesiologists score of 1, 2, or 3. This score is a way to describe a patient’s overall health before surgery, with 1 being healthy and 3 having more health issues.
Must be between the ages of 18 and 80 years old.
Both men and women can participate.
Participants should not be from a vulnerable population, meaning they should not be in a situation where they are at a higher risk of harm or exploitation.

Who Cannot Join the Study?

Patients who are not undergoing inguinal hernia surgery or knee replacement surgery.
Patients who are not experiencing or at risk of developing chronic postoperative pain. This is pain that continues for a long time after surgery.
Patients who are outside the specified age range for the study.
Patients who belong to a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Reinier de Graaf Groep	Delft	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Recruiting	01.05.2019

Trial locations

Investigated drugs:

Tapentadol Hydrochloride

Tapentadol is a medication used in this trial to prevent chronic pain after surgery. It is an opioid pain reliever that works by changing the way the brain and nervous system respond to pain. In this study, it is being tested to see if it can help reduce the risk of developing long-term pain after surgeries like inguinal hernia repair and knee replacement.

Investigated diseases:

Procedural pain

Chronic Postoperative Pain – This condition occurs when pain persists for an extended period following surgery, beyond the usual healing time. It can develop after various surgical procedures, such as inguinal hernia repair or knee replacement. The pain may be continuous or intermittent and can vary in intensity. It often results from nerve damage or changes in the nervous system due to surgery. Over time, this pain can affect a person’s daily activities and quality of life. Understanding the mechanisms behind its development is crucial for prevention and management.

Trial ID:

2024-511010-21-00

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider